AJMC®’s Institute for Value-Based Medicine® partners with Intermountain Health to host event: Optimizing Kidney Health: Advances in Proactive Care Models
September 23, 2024 12:00 ET
|
The American Journal of Managed Care
CRANBURY, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is pleased to...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
September 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
September 23, 2024 08:00 ET
|
OPKO Health, Inc.
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief...
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis
September 23, 2024 08:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the resubmission of a New Drug Application (NDA) to the...
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
September 23, 2024 07:35 ET
|
ALTERITY THERAPEUTICS LIMITED
- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept....
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
September 23, 2024 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024)
September 23, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL (sublingual cyclobenzaprine HCl) Composition and methods patents based on the...
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
September 23, 2024 07:00 ET
|
Black Diamond Therapeutics, Inc
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target...
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...